Get the Stockscreener App
11.33
1.34%
0.15
After Hours:
11.33
Indivior Plc stock is traded at $11.33, with a volume of 521.45K.
It is up +1.34% in the last 24 hours and up +25.89% over the past month.
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
See More
Previous Close:
$11.18
Open:
$11.06
24h Volume:
521.45K
Relative Volume:
0.71
Market Cap:
$1.39B
Revenue:
$1.12B
Net Income/Loss:
$5.00M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-383.00M
1W Performance:
+7.09%
1M Performance:
+25.89%
6M Performance:
-34.77%
1Y Performance:
-29.58%
1-Day Range:
$10.94
$11.47
1-Week Range:
$10.45
$11.47
52-Week Range:
$7.33
$23.22
Indivior Plc Stock (INDV) Company Profile
Compare INDV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Plc
|
11.33 | 1.39B | 1.12B | 5.00M | -383.00M | 0.00 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Indivior Plc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
Indivior Plc Stock (INDV) Latest News
Clark Estates Inc. NY Takes Position in Indivior PLC (NASDAQ:INDV) - MarketBeat
Indivior’s Strategic Share Repurchase Initiative - TipRanks
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit with the Schall Law Firm - GuruFocus.com
(INDV) Trading Report - Stock Traders Daily
Levi & Korsinsky Announces the Filing of a Securities Class Acti - GuruFocus.com
Valence8 US LP Buys New Position in Indivior PLC (NASDAQ:INDV) - MarketBeat
Indivior Announces Q3 2024 Financial Results - GuruFocus.com
Indivior to Engage with Investors at Healthcare Conference - TipRanks
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site - GuruFocus.com
Shareholders that lost money on Indivior PLC(INDV) should contac - GuruFocus.com
Indivior Responds to Publication of a Letter by Oaktree Capital - GuruFocus.com
The Gross Law Firm Announces the Filing of a Securities Class Ac - GuruFocus.com
Addex Stock Soars on Crucial Update From Indivior Research Deal - MSN
Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024 - The Malaysian Reserve
Naloxone Market Growth in Future Scope 2024-2031 | EMERGENT, - openPR
Indivior shares Sublocade trial findings at CSAM conference - TipRanks
Indivior PLC Executes Strategic Share Repurchase - TipRanks
Indivior (LON:INDV) Stock Passes Above 50 Day Moving AverageHere's Why - MarketBeat
Substance Abuse Treatment Market Future Business - openPR
Indivior’s Voting Rights Shift with Madison Avenue - TipRanks
Suboxone Tooth Decay Lawsuit - Lawsuit Information Center Blog
A Piece Of The Puzzle Missing From Indivior PLC's (LON:INDV) 35% Share Price Climb - Simply Wall St
SCOPIA CAPITAL MANAGEMENT LP Adjusts Stake in Indivior PLC - GuruFocus.com
Indivior Extends Board Tenure Amidst Shareholder Changes - TipRanks
Richmond InnoChesterfield pharma company Indivior subject to activist shareholder push - The Business Journals
Learn to Evaluate (INDV) using the Charts - Stock Traders Daily
Indivior PLC (INDV) Shares Down 3.04% on Nov 12 - GuruFocus.com
Deerfield’s Strategic Stake Acquisition in Indivior - TipRanks
Indivior jumps amid investor letter, takeover speculation (update) - MSN
Indivior (LON:INDV) Shares Pass Below 200-Day Moving AverageShould You Sell? - MarketBeat
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior - The Malaysian Reserve
Indivior Boosts Shareholder Value with Repurchase Program - TipRanks
Oaktree Capital urges UK's Indivior to refresh board - Reuters
Indivior says it remains open-minded on activist investor Oaktree's proposals - Proactive Investors USA
Indivior Engages with Oaktree on Value Proposals - TipRanks
Indivior jumps amid takeover speculation - MSN
Oaktree Capital calls on Indivior to refresh board of directors - ShareCast
A Setback for Suboxone Film Plaintiffs: Northern District of Ohio's Dismissal Decision - LawyersandSettlements.com
AlphaCentric Advisors LLC Invests $2.36 Million in Indivior PLC (NASDAQ:INDV) - MarketBeat
Indivior completes refinancing of secured term loan - Marketscreener.com
Indivior Extends Its Debt Maturity With Refinancing of Term Loan - Bloomberg
Indivior Boosts Liquidity with $400 Million Refinancing - TipRanks
Indivior PLC Completes Refinance of Secured Term Loan - Marketscreener.com
VELA Investment Management LLC Acquires 108,435 Shares of Indivior PLC (NASDAQ:INDV) - MarketBeat
When the Price of (INDV) Talks, People Listen - Stock Traders Daily
Indivior Announces Total Voting Rights Update - TipRanks
Indivior (LON:INDV) Stock Price Crosses Below 200 Day Moving AverageWhat's Next? - MarketBeat
Sublocade shows promise in opioid disorder recovery By Investing.com - Investing.com Australia
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month - The Malaysian Reserve
Indivior Plc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.83%
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):